乳腺癌改良根治术后复发转移1例报道
A case report of recurrence and metastasis of breast cancer after modified radical mastectomy
焦茹茹 1刘方丽1
作者信息
- 1. 山东省菏泽市牡丹人民医院综合治疗放疗病区,山东菏泽 274000
- 折叠
摘要
乳腺癌是女性最常见的恶性肿瘤之一,在乳腺癌各亚型中,人表皮生长因子受体 2(HER2)阳性乳腺癌恶性程度较高,预后较差,目前抗HER2 靶向治疗已成为HER2 阳性乳腺癌的主要治疗方法.本文报道1例乳腺癌改良根治术后复发转移的HER2 阳性乳腺癌患者,该患者行右侧乳腺癌改良根治术后 5 年发生淋巴结转移、肝转移、骨转移、肺转移癌,采用伊尼妥单抗联合吡咯替尼二线治疗方案治疗后,病情持续稳定,目前无进展生存期已达17 个月.
Abstract
Breast cancer is one of the most common malignant tumors in women.Among all subtypes of breast cancer,human epidermal growth factor receptor 2(HER2)positive breast cancer has a high degree of malignancy and a poor prognosis.At present,anti HER2 targeted therapy has become the main treatment method for HER2 positive breast cancer.This paper reported a case of HER2 positive breast cancer with recurrence and metastasis of breast cancer after modified radical mastectomy.The patient had lymph node metastasis,liver metastasis,bone metastasis,and lung metastasis five years after modified radical mastectomy for right breast cancer.After the treatment with the second-line treatment scheme of Inetetamab combined with Pyrotinib,the condition remained stable and the progression free survival period has reached 17 months at present.
关键词
乳腺癌/术后复发/转移癌/伊尼妥单抗/吡咯替尼Key words
Breast cancer/Postoperative recurrence/Metastatic cancer/Inetetamab/Pyrotinib引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据